Opendata, web and dolomites

oncNGS SIGNED

NGS diagnostics in 21st century oncology: the best, for all, at all times

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 oncNGS project word cloud

Explore the words cloud of the oncNGS project. It provides you a very rough idea of what is the project "oncNGS" about.

efficient    germany    marker    affordable    kit    limited    tests    malignancies    biomedical    hcl    procurement    valuable    validation    six    buyers    launching    reporting    tumours    ngs    dna    analytical    bcr    suppliers    decision    statistics    leads    belgium    clinical    inca    ico    oncngs    medicines    eight    spain    solid    diverse    rna    liquid    diagnostics    entities    compare    precommercial    aquas    sc    strategy    hc    phases    property    outcome    intellectual    cancer    freedom    operate    ict    lowering    perform    italy    therapies    inequities    interpretation    rights    lmu    contracted    medical    molecular    commercial    innovative    profiling    solutions    market    ibsal    breaking    unmet    biopsies    thanks    patients    pan    vhio    pooling    obtain    solution    procedure    experts    lymphomas    consist    tumour    ic    supplies    establishment    expert    acc    material    ijb    capacity    haematologic    treatments    equal    unacceptable    dcp    france    prototyping    competitive   

Project "oncNGS" data sheet

The following table provides information about the project.

Coordinator
SCIENSANO 

Organization address
address: JULIETTE WYTSMANSTRAAT 14
city: ELSENE
postcode: 1050
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 12˙221˙843 €
 EC max contribution 10˙999˙659 € (90%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme PCP
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SCIENSANO BE (ELSENE) coordinator 8˙436˙825.00
2    ALLEANZA CONTRO IL CANCRO IT (ROMA) participant 434˙614.00
3    INSTITUT CATALA D'ONCOLOGIA ES (L'HOSPITALET DEL LLOBREGAT) participant 314˙317.00
4    HOSPICES CIVILS DE LYON FR (LYON) participant 300˙375.00
5    INSTITUT JULES BORDET BE (BRUXELLES) participant 300˙375.00
6    INSTITUT CURIE FR (PARIS) participant 300˙111.00
7    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 252˙000.00
8    AGENCIA DE QUALITAT I AVALUACIO SANITARIES DE CATALUNYA ES (BARCELONA) participant 189˙247.00
9    DE CLERCQ & PARTNERS BE (SINT-MARTENS-LATEM) participant 189˙225.00
10    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 89˙367.00
11    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 48˙312.00
12    FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON ES (SORIA) participant 48˙296.00
13    INSTITUT NATIONAL DU CANCER GIP FR (BOULOGNE BILLANCOURT) participant 48˙296.00
14    STICHTING KANKERREGISTER - FONDATION REGISTRE DU CANCER BE (Brussels) participant 48˙296.00

Map

 Project objective

oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCNGS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCNGS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More  

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More  

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More